Royal Bank of Canada’s Sciclone Pharmaceuticals Inc SCLN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-5,618
| Closed | -$63K | – | 7320 |
|
|
2017
Q3 | $63K | Buy |
5,618
+3,996
| +246% | +$44.1K | ﹤0.01% | 5292 |
|
|
2017
Q2 | $18K | Buy |
1,622
+22
| +1% | +$220 | ﹤0.01% | 5592 |
|
|
2017
Q1 | $16K | Sell |
1,600
-2,232
| -58% | -$22.3K | ﹤0.01% | 5756 |
|
|
2016
Q4 | $41K | Buy |
3,832
+2,209
| +136% | +$22.1K | ﹤0.01% | 5379 |
|
|
2016
Q3 | $16K | Sell |
1,623
-77
| -5% | -$839 | ﹤0.01% | 5636 |
|
|
2016
Q2 | $22K | Sell |
1,700
-500
| -23% | -$6.55K | ﹤0.01% | 5482 |
|
|
2016
Q1 | $24K | Sell |
2,200
-30,085
| -93% | -$268K | ﹤0.01% | 5424 |
|
|
2015
Q4 | $297K | Buy |
32,285
+29,301
| +982% | +$245K | ﹤0.01% | 4238 |
|
|
2015
Q3 | $20K | Sell |
2,984
-46,695
| -94% | -$400K | ﹤0.01% | 5577 |
|
|
2015
Q2 | $487K | Buy |
49,679
+1,532
| +3% | +$14K | ﹤0.01% | 3619 |
|
|
2015
Q1 | $427K | Buy |
48,147
+46,347
| +2,575% | +$369K | ﹤0.01% | 3666 |
|
|
2014
Q4 | $16K | Sell |
1,800
-200
| -10% | -$1.62K | ﹤0.01% | 5472 |
|
|
2014
Q3 | $14K | Sell |
2,000
-1,500
| -43% | -$8.99K | ﹤0.01% | 5390 |
|
|
2014
Q2 | $18K | Buy |
3,500
+1,000
| +40% | +$4.87K | ﹤0.01% | 5243 |
|
|
2014
Q1 | $11K | Buy |
2,500
+1,500
| +150% | +$7.25K | ﹤0.01% | 5410 |
|
|
2013
Q4 | $5K | Sell |
1,000
-19,688
| -95% | -$94.7K | ﹤0.01% | 5621 |
|
|
2013
Q3 | $105K | Buy |
20,688
+19,402
| +1,509% | +$108K | ﹤0.01% | 4453 |
|
|
2013
Q2 | $6K | Buy |
+1,286
| New | +$6.12K | ﹤0.01% | 5429 |
|
Royal Bank of Canada's SCLN Position: Q4 2017 in Review
Royal Bank of Canada sold out of Sciclone Pharmaceuticals Inc (SCLN) in Q4 2017, closing a stake of 5,618 shares — an estimated $63K sold.
Royal Bank of Canada first reported a position in SCLN in Q2 2013 and held it in 18 quarters. The position peaked at $487K in Q2 2015. 0 funds tracked by Wall St. Rank hold SCLN as of Q4 2017.
- Royal Bank of Canada reported no remaining Sciclone Pharmaceuticals Inc position as of Q4 2017 after selling out during the quarter.
- Royal Bank of Canada sold 5,618 Sciclone Pharmaceuticals Inc shares in Q4 2017, an estimated $63K.
- Royal Bank of Canada first reported a position in Sciclone Pharmaceuticals Inc in Q2 2013 and held it in 18 quarters.
- Royal Bank of Canada's Sciclone Pharmaceuticals Inc position peaked at $487K in Q2 2015.
- 0 funds tracked by Wall St. Rank held Sciclone Pharmaceuticals Inc as of Q4 2017.
Based on Royal Bank of Canada's 13F filing for Q4 2017, filed 14 Feb 2018.